You, J. H. S., Cho, W. C. S., Ming, W., Li, Y., Kwan, C., Au, K., & Au, J. S. (2021). EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis. PLoS One.

You, Joyce H. S., William C. S. Cho, Wai-kit Ming, Yu-chung Li, Chung-kong Kwan, Kwok-hung Au, and Joseph Siu-kie Au. "EGFR Mutation-guided Use of Afatinib, Erlotinib and Gefitinib for Advanced Non-small-cell Lung Cancer in Hong Kong – A Cost-effectiveness Analysis." PLoS One 2021.

You, Joyce H. S., et al. "EGFR Mutation-guided Use of Afatinib, Erlotinib and Gefitinib for Advanced Non-small-cell Lung Cancer in Hong Kong – A Cost-effectiveness Analysis." PLoS One 2021.